JohnASunyeczMD

PubMed

• 139 citations
  The use of calcium and vitamin D in the management of osteoporosis
  John A Sunyecz
  Therapeutics and Clinical Risk Management. 2008-08-08
• 35 citations
  Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
  J. A. Sunyecz, L. Mucha, O. Baser, Charles E. Barr, M. M. Amonkar
  Osteoporosis International. 2008-03-20
• 8 citations
  Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
  John Sunyecz
  Clinical Interventions in Aging. 2008-12-05

Abstracts/Posters

• Women’s stated preference for once-monthly versus once-weekly osteoporosis treatment regimens.
  Utian, W, Sunyecz, J.A, ACOG Annual Clinical Meeting
• The effect of the “Perimenopause and Menopause Survival Kit” in providing information and recommendations for the menopause transition.
  Sunyecz, J.A., Sunyecz, L.A, North American Menopause Society meeting, Chicago, IL
• The effect of a menopause Internet site on the dissemination of education and information and its influence on health care practices.
  Sunyecz, J.A., Sunyecz, L.A, North American Menopause Society meeting, Chicago, IL
• Average woman experiences nearly seven symptoms of menopause plus other health concerns.
  Sunyecz, J.A., Drexler, A.J, North American Menopause Society meeting, Washington, D.C
• Menopausal women’s current impressions of hormonal therapy.
  Sunyecz, J.A., Drexler, A.J, North American Menopause Society meeting, Washington, D.C
• Days of therapy improve with weekly dosing, but remain inadequate.
  Sunyecz, J.A., Gallagher, R., Smith, J.C., MacCosbe, P.E, North American Menopause Society meeting, Washington, D.C
• Review of 3 Claims Database Studies: Consistent Improvement in Bisphosphonate Persistence with Less Frequent Dosing.
  Gold, D, Sunyecz, J. Kamel, H, Leslie, R, 14 th Annual Congress on Women’s Health
• Consistent improvement in bisphosphonate persistence with less frequent dosing: Review comparing results of three database studies.
  Gold, D.T., Cramer, J.A., Sunyecz, J.A., Amonkar, M.M., Ettinger, M.P, International Society for Clinical Densitometry
• Continued improvement in bone mineral density observed from 1 to 2 years after treatment with monthly oral ibandronate.
  Sunyecz, J, Lewiecki, EM, Emkey, R, et al, North American Menopause Society Meeting
• Healthcare costs and utilization are reduced for women adherent to bisphosphonate therapy.
  Sunyecz, J, Curtis, JR, Barr, C, et al, North American Menopause Society Meeting
• Persistence with monthly ibandronate and weekly bisphosphonates: an early look.
  Silverman, SL, Derman, R, Sunyecz, J, et al, North American Menopause Society Meeting
• Changing Awareness and Management of Calcium and Vitamin D Deficiencies: The Role of the Pharmacist in Bone Health and Osteoporosis.
  Sunyecz, JA, PowerPak CE
• Better clinical response for once-monthly versus daily oral ibandronate.
  Sunyecz, J.A, ACOG Annual Clinical Meeting
• Monthly Ibandronate Suppresses Serum CTX-1 Within 3 Days and Maintains a Monthly Fluctuating Pattern of Suppression.
  Binkley, N, Silverman, S, Simonelli, Sunyecz, J, Santiago, Kohles, Dasic, Osteoporosis International
• Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis.
  Sunyecz, J.A., Gallaher, R., MacCosbe, P.E, The Female Patient
• Improving Patient Outcomes with Osteoporosis Drug Therapy.
  Sunyecz, JA, PowerPak CE
• Mobile 2 Year: Efficacy and tolerability of once-monthly ibandronate in postmenopausal osteoporosis.
  Dasic, G, Lewiecki, E, Miller, P, Sunyecz, J, Emkey, R, ACOG Annual Clinical Meeting
• Better adherence to bisphosphonate therapy is associated with reduced nonvertebral fracture risk.
  Sunyecz, J.A., Bachman, G., Abbottt, T., Barr, C, ACOG Annual Clinical Meeting
• Review of 3 Claims Database Studies: Consistent Improvement in Bisphosphonate Persistence with Less Frequent Dosing.
  Gold, D, Sunyecz, J. Kamel, H, Leslie, R, 14 th Annual Congress on Women’s Health
• Consistent improvement in bisphosphonate persistence with less frequent dosing: Review comparing results of three database studies.
  Gold, D.T., Cramer, J.A., Sunyecz, J.A., Amonkar, M.M., Ettinger, M.P, International Society for Clinical Densitometry
• Continued improvement in bone mineral density observed from 1 to 2 years after treatment with monthly oral ibandronate.
  Sunyecz, J, Lewiecki, EM, Emkey, R, et al, North American Menopause Society Meeting
• Healthcare costs and utilization are reduced for women adherent to bisphosphonate therapy.
  Sunyecz, J, Curtis, JR, Barr, C, et al, North American Menopause Society Meeting
• Persistence with monthly ibandronate and weekly bisphosphonates: an early look.
  Silverman, SL, Derman, R, Sunyecz, J, et al, North American Menopause Society Meeting
• Changing Awareness and Management of Calcium and Vitamin D Deficiencies: The Role of the Pharmacist in Bone Health and Osteoporosis.
  Sunyecz, JA, PowerPak CE
• The Use of Combination Therapy in Osteoporosis: Bisphosphonates Calcium and Vitamin D.
  Sunyecz, JA, PowerPak CE
• Join now to see all

Lectures

• Practitioner Panel: Osteoporosis. 
  Pharmaceutical Representatives, Exceeding Expectations Meeting, Roche Pharmaceuticals, Las Vegas
• Clinical Advisory Member for 'Postpartum Counseling Guide - A quick reference guide for clinicians'. 
  ARHP
• Panelist for ‘Managing Menopausal Symptoms in the Wake of WHI’ Medical Crossfire. 
• Panelist for ‘The Surgeon General's Report on Bone Health: Applications for the Clinician. 
  Medical Crossfire
• Bio-Identical Hormone Therapy…Is it natural? Is it better? 
  Consumer educational brochure, produced for MenopauseRx, Inc
• Beyond Oral Contraceptives: Improving the Quality of Life for the Female Patient. 
  CME presentation to Wheeling, WVa. Ob/Gyn meeting
• Calcium in Pregnancy and Beyond. 
  GlaxoSmithKline representatives, Orlando, FL
• Review of ACET Trial for Urinary Incontinence. 
  Pharmacia representatives, teleconference
• Stress Incontinence: Pathophysiology and Treatment Options. 
  GSK scientific committee
• Relationship of Weight and Oral Contraceptive Use Failure. 
  Ob/Gyn roundtable
• Explore the differences between the menopause and perimenopause, including symptoms and treatment options by a board certified gynecologist. Learn about the importan... 
  Pathways to Beauty and Well-Being Event
• Total Laparoscopic Hysterectomy: Achieving the Best Technique for Vaginal Cuff Closure. 
  AAGL Global Congress of Minimally Invasive Gynecology
• Hormone Therapy…Bio-Identical Treatment Options. 
  Wheeling, WV Ob/Gyn Society
• Abnormal Bleeding…Alternatives to Hysterectomy. 
  local community group
• Practitioner Panel: Osteoporosis. Pharmaceutical Representatives. 
  Roche Pharmaceuticals, Boston, MA
• Pregnancy: An Ob/Gyn’s Perspective. 
  GSK Calcium Summit, Pittsburgh, PA
• Roche/GSK. Numerous presentations related to Osteoporosis diagnosis and treatment options. 
• Ortho Women’s Health & Urology. Numerous presentations to Health Care Providers related to Interstitial Cystitis diagnosis and treatment options. 
• Similar Bone Mineral Density Gains for Oral Monthly Ibandronate and Weekly Alendronate in Postmenopausal Osteoporosis. 
  American College of Ob/Gyn Annual Clinical Meeting, New Orleans
• The Use of a Vaginal Moisturizer Containing Vitamin B3 (Vibrel™ for Women) in Perimenopausal and Menopausal Women Complaining of Sexual Dysfunction: Results of a Pil... 
  North American Menopause Society meeting, San Diego, CA
• Amgen. Numerous presentations to Health Care Providers related to Osteoporosis management and treatment options. 
• Making Menopause Manageable. 
  29 th Annual CME Conference of Virginia Academy of Physician Assistants. Virginia Beach, VA
• Join now to see all